Related Experiment Video
Updated: May 21, 2026
10:44
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
[PARP inhibitors--theoretical basis and clinical application].
Sylwia Dębska1, Joanna Kubicka, Rafał Czyżykowski
1Klinika Chemioterapii Nowotworów Katedry Onkologii UM w Łodzi, Szpital Specjalistyczny im. M. Kopernika w Łodzi. sylwia.debska@o2.pl
Postepy Higieny I Medycyny Doswiadczalnej (Online)
|June 19, 2012
Summary
Poly (ADP-ribose) polymerases (PARP) inhibitors show promise for treating BRCA1/2-deficient cancers by exploiting synthetic lethality. Clinical trials with PARP inhibitors like iniparib and olaparib are advancing cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Poly (ADP-ribose) polymerases (PARP) are crucial enzymes involved in DNA repair, genomic stability, and apoptosis.
- PARP1 specifically repairs single-strand DNA breaks (SSBs); its inhibition leads to accumulation of SSBs and subsequent double-strand breaks (DSBs).
Purpose of the Study:
- To present the theoretical basis of PARP inhibitors' action.
- To critically review key clinical trials of PARP inhibitors in cancer treatment.
Main Methods:
- Review of scientific literature on PARP enzymes and their inhibitors.
- Analysis of clinical trial data for PARP inhibitors in breast and ovarian cancers.
Main Results:
- PARP inhibition induces synthetic lethality in BRCA1/2-deficient cancer cells.
- PARP inhibitors demonstrate synergism with genotoxic chemotherapy and radiotherapy.
- Phase I and II trials show promising results for iniparib and olaparib in triple-negative breast and ovarian cancers.
Conclusions:
- PARP inhibitors represent a targeted therapy approach for BRCA1/2-mutated cancers.
- Further clinical studies are warranted to optimize the application of PARP inhibitors in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...